🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07317791
Starting soon Not applicable

Cough Flow as a Criterion Decannulation Threshold in Prolonged Tracheostomy Patients

NCT07317791 · tracked via the Priya Life Science China tracker
Sponsor
Hongying Jiang, MD
Phase
Not applicable
Started
2026-01-01
Last updated
2026-01-21

Condition(s) studied

Tracheostomy

Investigational drug(s) / intervention(s)

standardized tracheostomy decannulation protocol

standardized tracheostomy decannulation protocol: Step 1: Confirm that the patient is clinically stable. Step 2: Speaking valve (SV) with transtracheal end-expiratory pressure (TTPEE) measurement. Step 3: Measure the CFsv. Step 4: Continue wearing the SV for 4 hours. During this period, suctioning is not performed via the tracheostomy tube. Step 5: Assess readiness for decannulation. The CFsv is measured again prior to decannulation. If the value exceeds 100 L/min, decannulation is performed.

Study summary

Background: International studies have proposed a cough peak flow (CPF) of ≥160 L/min as a reference threshold for safe decannulation. However, this measurement requires prior removal of the tracheostomy tube, which is often difficult for Chinese patients and their families to accept due to cultural and safety concerns. Additionally, there is a lack of rapid, user-friendly, and widely applicable quantitative tools in clinical practice within ICUs or rehabilitation specialties in China. Moreover, the heterogeneity among domestic patient populations with different underlying conditions (such as neuromuscular diseases, spinal cord injuries, stroke, and respiratory failure) makes it challenging to apply a single foreign-derived indicator. In our center's prospective study from 2019 to 2022(Respiratory Research 2024;25:128), the investigators proposed and preliminarily validated that a cough flow measured with tracheostomy tube and speaking valve (CFSV) \>100 L/min could serve as a threshold for safe decannulation. Among 193 patients with long-term tracheostomy tubes, 105 were decannulated based on this threshold, with a success rate of 98.1%. Only two cases required reintubation within 48 hours (1.9%), and the six-month reintubation rate was 2.9%, which is significantly better than previously reported domestic and international data (reintubation rates of 5-15%). For patients with insufficient CFSV, after an average of 26 days of individualized cough enhancement rehabilitation, 91% achieved the threshold and ultimately succeeded in decannulation. This suggests that 100 L/min may be a more physiologically appropriate threshold for Chinese (and even East Asian) populations with indwelling tracheostomy tubes, and that CFSV combined with systematic rehabilitation interventions can significantly improve decannulation rates. However, these conclusions are derived from single-center data with a limited sample size, and the diversity of diseases and regional variations in medical standards may affect generalizability. Therefore, there is an urgent need for multicenter, large-sample prospective studies to validate the effectiveness, accuracy, and feasibility of CFSV \>100 L/min as a quantitative standard for safe decannulation.

Eligibility

Sex
ALL
Min age
18 Years
Max age
90 Years
Healthy volunteers
No
Inclusion Criteria: * Age ≥18 years * Tracheostomy tube in place for ≥14 days * Weaned from ventilator for more than 48 hours, or in a state of spontaneous breathing * Patient and family members have provided informed consent Exclusion Criteria: * Severe craniofacial deformity preventing CFsv measurement * Known obstructive upper airway pathology precluding tracheostomy tube removal * Laryngopharyngeal trauma * Inability to tolerate cuff deflation

Primary outcome measure(s)

Trial sites (5)

FacilityCityRegionStatus
Beijing Rehabilitation Hospital, Capital Medical University, Beijing,China Beijing Beijing Municipality
Hunan Rehabilitation Hospital Hunan Hunan
Jiangbin Hospital of Guangxi Zhuang Autonomous Region Guangxi Jiangbin
YanBian University Hospital Jilin City Yanbian
Zhengzhou Central Hospital Affiliated to Zhengzhou University Henan Zhengzhou

More Hongying Jiang, MD trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07317791 on ClinicalTrials.gov ↗ ← All trials in China